|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/12/20 Rubius Therapeutics, Inc. 10-K 12/31/19 86:13M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.72M
2: EX-4.1 Instrument Defining the Rights of Security Holders HTML 59K
3: EX-10.9 Material Contract HTML 120K
4: EX-21.1 Subsidiaries List HTML 25K
5: EX-23.1 Consent of Experts or Counsel HTML 25K
6: EX-31.1 Certification -- §302 - SOA'02 HTML 33K
7: EX-31.2 Certification -- §302 - SOA'02 HTML 33K
8: EX-32.1 Certification -- §906 - SOA'02 HTML 27K
9: EX-32.2 Certification -- §906 - SOA'02 HTML 27K
67: R1 Document and Entity Information HTML 62K
22: R2 Consolidated Balance Sheets HTML 108K
48: R3 Consolidated Balance Sheets (Parenthetical) HTML 44K
77: R4 Consolidated Statements of Operations and HTML 74K
Comprehensive Loss
65: R5 Consolidated Statements of Operations and HTML 28K
Comprehensive Loss (Parenthetical)
21: R6 Consolidated Statements of Convertible Preferred HTML 134K
Stock and Stockholders? Equity (Deficit)
47: R7 Consolidated Statements of Convertible Preferred HTML 30K
Stock and Stockholders? Equity (Deficit)
(Parenthetical)
75: R8 Consolidated Statements of Cash Flows HTML 143K
69: R9 Nature of the Business and Basis of Presentation HTML 35K
73: R10 Summary of Significant Accounting Policies HTML 158K
61: R11 Investments and Fair Value of Financial Assets and HTML 173K
Liabilities
24: R12 Property, Plant and Equipment, Net HTML 55K
51: R13 Accrued Expenses and Other Current Liabilities HTML 46K
74: R14 Debt HTML 67K
62: R15 Convertible Preferred Stock HTML 31K
25: R16 Warrants to Purchase Convertible Preferred Stock HTML 29K
52: R17 Equity HTML 32K
72: R18 Stock-Based Compensation HTML 206K
63: R19 Income Taxes HTML 121K
26: R20 Commitments and Contingencies HTML 34K
35: R21 Leases HTML 102K
79: R22 Net Loss Per Share HTML 85K
53: R23 Related Parties HTML 35K
27: R24 Selected Quarterly Financial Data (Unaudited) HTML 106K
36: R25 Summary of Significant Accounting Policies HTML 217K
(Policies)
80: R26 Summary of Significant Accounting Policies HTML 125K
(Tables)
54: R27 Investments and Fair Value of Financial Assets and HTML 174K
Liabilities (Tables)
28: R28 Property, Plant and Equipment, Net (Tables) HTML 51K
34: R29 Accrued Expenses and Other Current Liabilities HTML 46K
(Tables)
49: R30 Debt (Tables) HTML 62K
23: R31 Stock-Based Compensation (Tables) HTML 191K
68: R32 Income Taxes (Tables) HTML 117K
78: R33 Leases (Tables) HTML 97K
46: R34 Net Loss Per Share (Tables) HTML 86K
20: R35 Selected Quarterly Financial Data (Unaudited) HTML 106K
(Tables)
64: R36 Nature of the Business and Basis of Presentation HTML 53K
(Details)
76: R37 Summary of Significant Accounting Policies HTML 51K
(Details)
50: R38 Summary of Significant Accounting Policies - HTML 36K
Estimated useful life (Details)
19: R39 Summary of Significant Accounting Policies - HTML 111K
Recently Adopted Accounting Pronouncements
(Details)
40: R40 Investments and Fair Value of Financial Assets and HTML 96K
Liabilities (Details)
33: R41 Property, Plant and Equipment, Net (Details) HTML 73K
56: R42 Accrued Expenses and Other Current Liabilities HTML 42K
(Details)
83: R43 Debt (Details) HTML 87K
39: R44 Debt - Current and Non current (Details) HTML 39K
32: R45 Convertible Preferred Stock (Details) HTML 62K
55: R46 Warrants to Purchase Convertible Preferred Stock HTML 50K
(Details)
82: R47 Equity (Details) HTML 70K
41: R48 Stock-Based Compensation (Details) HTML 57K
31: R49 Stock-Based Compensation - Employees, directors HTML 34K
and non-employees (Details)
16: R50 Stock-Based Compensation - Granted to HTML 46K
non-employees, prior to the adoption of ASU
2018-07 (Details)
44: R51 Stock-Based Compensation - Option activity HTML 80K
(Details)
70: R52 Stock-Based Compensation - Performance based stock HTML 82K
options (Details)
59: R53 Stock-Based Compensation - Restricted Common Stock HTML 117K
(Details)
17: R54 Stock-Based Compensation - Compensation expense HTML 72K
(Details)
45: R55 Income Taxes (Details) HTML 53K
71: R56 Income Taxes - U S federal statutory income tax HTML 49K
rate (Details)
60: R57 Income Taxes - Net deferred tax assets (Details) HTML 60K
18: R58 Income Taxes - Valuation allowance for deferred HTML 29K
tax assets (Details)
42: R59 Commitments and Contingencies - Collaborative HTML 33K
Arrangements And Non-collaborative Arrangement
(Details)
85: R60 Commitments and Contingencies - Defined HTML 33K
Contribution Plan (Details)
57: R61 Leases (Details) HTML 61K
29: R62 Leases - Minimum lease payments (Details) HTML 67K
37: R63 Leases - Sublease (Details) HTML 33K
86: R64 Leases - Lease Portfolio (Details) HTML 50K
58: R65 Net Loss Per Share - Weighted Average Shares HTML 45K
(Details)
30: R66 Net Loss Per Share - Antidilutive Securities HTML 42K
(Details)
38: R67 Related Parties (Details) HTML 84K
84: R68 Selected Quarterly Financial Data (Unaudited) HTML 37K
(Details)
43: XML IDEA XML File -- Filing Summary XML 151K
66: EXCEL IDEA Workbook of Financial Reports XLSX 104K
10: EX-101.INS XBRL Instance -- ruby-20191231 XML 2.67M
12: EX-101.CAL XBRL Calculations -- ruby-20191231_cal XML 191K
13: EX-101.DEF XBRL Definitions -- ruby-20191231_def XML 730K
14: EX-101.LAB XBRL Labels -- ruby-20191231_lab XML 1.64M
15: EX-101.PRE XBRL Presentations -- ruby-20191231_pre XML 1.23M
11: EX-101.SCH XBRL Schema -- ruby-20191231 XSD 197K
81: ZIP XBRL Zipped Folder -- 0001558370-20-002475-xbrl Zip 213K
| ruby_Ex32_1 |
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Rubius Therapeutics, Inc. (the “Company”) for the fiscal year ended December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Pablo J. Cagnoni, M.D., Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
Date: March 12, 2020 |
|
By: |
/s/ Pablo J. Cagnoni |
|
|
|
|
Pablo J. Cagnoni, M.D. |
|
|
|
|
Chief Executive Officer |
|
|
|
|
(Principal Executive Officer) |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/12/20 | 8-K, S-8 | ||
| For Period end: | 12/31/19 | 4 | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/27/23 Rubius Therapeutics, Inc. 10-K 12/31/22 77:7.2M 6/08/22 Rubius Therapeutics, Inc. S-3 6:1M Toppan Merrill/FA 2/25/22 Rubius Therapeutics, Inc. 10-K 12/31/21 74:10M Toppan Merrill Bridge/FA 2/23/21 Rubius Therapeutics, Inc. 10-K 12/31/20 82:12M Toppan Merrill Bridge/FA |